Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 1
1979 1
1980 3
1981 2
1982 2
1983 7
1984 5
1985 6
1986 7
1987 4
1988 6
1989 7
1990 4
1991 5
1992 4
1993 7
1994 5
1995 6
1996 5
1997 10
1998 14
1999 5
2000 10
2001 16
2002 11
2003 9
2004 19
2005 15
2006 16
2007 11
2008 14
2009 17
2010 11
2011 10
2012 11
2013 18
2014 11
2015 10
2016 8
2017 8
2018 10
2019 8
2020 2
2021 5
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

349 results
Results by year
Filters applied: . Clear all
Page 1
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators. Sitbon O, et al. Among authors: rubin lj. N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184. N Engl J Med. 2015. PMID: 26699168 Free article. Clinical Trial.
The physiological basis of pulmonary arterial hypertension.
Naeije R, Richter MJ, Rubin LJ. Naeije R, et al. Among authors: rubin lj. Eur Respir J. 2022 Jun 16;59(6):2102334. doi: 10.1183/13993003.02334-2021. Print 2022 Jun. Eur Respir J. 2022. PMID: 34737219 Free PMC article. Review.
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G; SERAPHIN Investigators. Pulido T, et al. Among authors: rubin lj. N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917. N Engl J Med. 2013. PMID: 23984728 Free article. Clinical Trial.
An overview of the 6th World Symposium on Pulmonary Hypertension.
Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. Galiè N, et al. Among authors: rubin lj. Eur Respir J. 2019 Jan 24;53(1):1802148. doi: 10.1183/13993003.02148-2018. Print 2019 Jan. Eur Respir J. 2019. PMID: 30552088 Free PMC article.
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Galiè N, et al. Among authors: rubin lj. N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687. N Engl J Med. 2015. PMID: 26308684 Free article. Clinical Trial.
Riociguat for the treatment of pulmonary arterial hypertension.
Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ; PATENT-1 Study Group. Ghofrani HA, et al. Among authors: rubin lj. N Engl J Med. 2013 Jul 25;369(4):330-40. doi: 10.1056/NEJMoa1209655. N Engl J Med. 2013. PMID: 23883378 Free article. Clinical Trial.
Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.
McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N. McLaughlin VV, et al. Among authors: rubin lj. J Am Coll Cardiol. 2018 Feb 20;71(7):752-763. doi: 10.1016/j.jacc.2017.12.010. J Am Coll Cardiol. 2018. PMID: 29447737 Free article. Clinical Trial.
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.
Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, Ghofrani HA, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Hoeper MM. Gaine S, et al. Among authors: rubin lj. Eur Respir J. 2017 Aug 17;50(2):1602493. doi: 10.1183/13993003.02493-2016. Print 2017 Aug. Eur Respir J. 2017. PMID: 28818881 Free PMC article. Clinical Trial.
Sildenafil citrate therapy for pulmonary arterial hypertension.
Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Galiè N, et al. Among authors: rubin lj. N Engl J Med. 2005 Nov 17;353(20):2148-57. doi: 10.1056/NEJMoa050010. N Engl J Med. 2005. PMID: 16291984 Free article. Clinical Trial.
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
Gaine S, Sitbon O, Channick RN, Chin KM, Sauter R, Galiè N, Hoeper MM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Tapson V, Ghofrani HA, Lang I. Gaine S, et al. Among authors: rubin lj. Chest. 2021 Jul;160(1):277-286. doi: 10.1016/j.chest.2021.01.066. Epub 2021 Feb 3. Chest. 2021. PMID: 33545163 Free article. Clinical Trial.
349 results